In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Alina Iovleva; Christi L. McElheny; Erin L. Fowler; Eric Cober; Erica S. Herc; Cesar A. Arias; Carol Hill; Keri Baum; Vance G. Fowler; Henry F. Chambers; Kerryl E. Greenwood-Quaintance; Robin Patel; David van Duin; Robert A. Bonomo; Yohei Doi

doi:10.1128/aac.01258-23

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Alina Iovleva, Christi L. McElheny, Erin L. Fowler, Eric Cober, Erica S. Herc, Cesar A. Arias, Carol Hill, Keri Baum, Vance G. Fowler, Henry F. Chambers, Kerryl E. Greenwood-Quaintance, Robin Patel, David van Duin, Robert A. Bonomo, Yohei Doi

Microbiology

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC₅₀/MIC₉₀ values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

Original language	English
Journal	Antimicrobial agents and chemotherapy
Volume	68
Issue number	3
DOIs	https://doi.org/10.1128/aac.01258-23
Publication status	Published - 03-2024

All Science Journal Classification (ASJC) codes

Pharmacology
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/aac.01258-23

Cite this

Iovleva, A., McElheny, C. L., Fowler, E. L., Cober, E., Herc, E. S., Arias, C. A., Hill, C., Baum, K., Fowler, V. G., Chambers, H. F., Greenwood-Quaintance, K. E., Patel, R., van Duin, D., Bonomo, R. A., & Doi, Y. (2024). In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. Antimicrobial agents and chemotherapy, 68(3). https://doi.org/10.1128/aac.01258-23

@article{c390c442bd7f4e34b86ddff795070a21,

title = "In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals",

abstract = "The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.",

author = "Alina Iovleva and McElheny, {Christi L.} and Fowler, {Erin L.} and Eric Cober and Herc, {Erica S.} and Arias, {Cesar A.} and Carol Hill and Keri Baum and Fowler, {Vance G.} and Chambers, {Henry F.} and Greenwood-Quaintance, {Kerryl E.} and Robin Patel and {van Duin}, David and Bonomo, {Robert A.} and Yohei Doi",

year = "2024",

month = mar,

doi = "10.1128/aac.01258-23",

language = "English",

volume = "68",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "3",

}

Iovleva, A, McElheny, CL, Fowler, EL, Cober, E, Herc, ES, Arias, CA, Hill, C, Baum, K, Fowler, VG, Chambers, HF, Greenwood-Quaintance, KE, Patel, R, van Duin, D, Bonomo, RA & Doi, Y 2024, 'In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals', Antimicrobial agents and chemotherapy, vol. 68, no. 3. https://doi.org/10.1128/aac.01258-23

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals. / Iovleva, Alina; McElheny, Christi L.; Fowler, Erin L. et al.
In: Antimicrobial agents and chemotherapy, Vol. 68, No. 3, 03.2024.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

AU - Iovleva, Alina

AU - McElheny, Christi L.

AU - Fowler, Erin L.

AU - Cober, Eric

AU - Herc, Erica S.

AU - Arias, Cesar A.

AU - Hill, Carol

AU - Baum, Keri

AU - Fowler, Vance G.

AU - Chambers, Henry F.

AU - Greenwood-Quaintance, Kerryl E.

AU - Patel, Robin

AU - van Duin, David

AU - Bonomo, Robert A.

AU - Doi, Yohei

PY - 2024/3

Y1 - 2024/3

N2 - The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

AB - The activity of a novel β-lactamase inhibitor combination, sulbactam-durlobactam (SUL-DUR), was tested against 87 colistin-resistant and/or cefiderocol-non-susceptible carbapenem-resistant Acinetobacter baumannii clinical isolates collected from U.S. hospitals between 2017 and 2019. Among them, 89% and 97% were susceptible to SUL-DUR and imipenem plus SUL-DUR, with MIC50/MIC90 values of 2 µg/mL/8 µg/mL and 1 µg/mL/4 µg/mL, respectively. The presence of amino acid substitutions in penicillin-binding protein 3, including previously reported A515V or T526S, was associated with SUL-DUR non-susceptibility.

UR - http://www.scopus.com/inward/record.url?scp=85187106929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85187106929&partnerID=8YFLogxK

U2 - 10.1128/aac.01258-23

DO - 10.1128/aac.01258-23

M3 - Article

C2 - 38289078

AN - SCOPUS:85187106929

SN - 0066-4804

VL - 68

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 3

ER -

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this